BeOne Medicines treatment of pancreatic cancer granted orphan status
BeOne Medicines' MTA-cooperative PRMT5 inhibitor was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency's website. Reference Link
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.